{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:39:02Z","timestamp":1790689142776,"version":"4.1.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taisho Pharmaceutical Co., Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor activity have various safety concerns, there is a growing demand for the development of novel hypnotics that act on targets other than GABAA receptor signaling to overcome the drawbacks of current medications. As an alternative target to generate novel hypnotics, the orexin system has recently gained much attention, and 3 dual orexin receptor antagonists (DORAs)\u2014suvorexant, lemborexant, and daridorexant\u2014were launched. However, some doses of these DORAs are associated with a higher incidence of somnolence compared to placebo. Vornorexant is a novel DORA designed to have an improved pharmacokinetic profile\u2014rapid absorption and the shortest half-life among existing DORAs to reduce the risk of residual activity, which has been confirmed in humans. Indeed, it has shown rapid sleep-promoting effects in patients with insomnia, maintaining its activity throughout the night but having a low incidence of next-day residual effects. In this review, we first provide an overview of the role of the orexin system in sleep\/wake balance and then describe the profile of a newly developed DORA, vornorexant, from drug discovery to clinical results.<\/jats:p>","DOI":"10.1093\/ijnp\/pyaf077","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:13:06Z","timestamp":1763644386000},"source":"Crossref","is-referenced-by-count":5,"title":["Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-4673","authenticated-orcid":false,"given":"Yukihiro","family":"Chino","sequence":"first","affiliation":[{"name":"Medical Information, Taisho Pharmaceutical Co., Ltd., \u00a0 Toshima-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Medical Information, Taisho Pharmaceutical Co., Ltd., \u00a0 Toshima-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Chaki","sequence":"additional","affiliation":[{"name":"Medical Information, Taisho Pharmaceutical Co., Ltd., \u00a0 Toshima-ku, Tokyo ,","place":["Japan"]},{"name":"Research Headquarters, Taisho Pharmaceutical Co., Ltd. , Kita-ku, Saitama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sato","sequence":"additional","affiliation":[{"name":"Medical Information, Taisho Pharmaceutical Co., Ltd., \u00a0 Toshima-ku, Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"key":"2025120516111165100_ref1","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S1474-4422(15)00021-6","article-title":"The neurobiology, investigation, and treatment of chronic insomnia","volume":"14","author":"Riemann","year":"2015","journal-title":"Lancet Neurol"},{"key":"2025120516111165100_ref2","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: definition, prevalence, etiology, and consequences","volume":"3","author":"Roth","year":"2007","journal-title":"J Clin Sleep Med"},{"key":"2025120516111165100_ref3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/15402002.2010.487450","article-title":"\"...Not just a minor thing, it is something major, which stops you from functioning daily\": quality of life and daytime functioning in insomnia","volume":"8","author":"Kyle","year":"2010","journal-title":"Behav Sleep Med"},{"key":"2025120516111165100_ref4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"2025120516111165100_ref5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1124\/pr.117.014381","article-title":"Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery","volume":"70","author":"Atkin","year":"2018","journal-title":"Pharmacol Rev"},{"key":"2025120516111165100_ref6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.phrs.2015.12.030","article-title":"Activation-induced regulation of GABAA receptors: is there a link with the molecular basis of benzodiazepine tolerance?","volume":"109","author":"Gravielle","year":"2016","journal-title":"Pharmacol Res"},{"key":"2025120516111165100_ref7","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/j.1742-1241.2009.02085.x","article-title":"Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder","volume":"63","author":"Hindmarch","year":"2009","journal-title":"Int J Clin Pract"},{"key":"2025120516111165100_ref8","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.sleep.2007.11.011","article-title":"Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam","volume":"9","author":"Gustavsen","year":"2008","journal-title":"Sleep Med"},{"key":"2025120516111165100_ref9","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s41999-022-00731-4","article-title":"Therapeutic dilemmas with benzodiazepines and Z-drugs: insomnia and anxiety disorders versus increased fall risk: a clinical review","volume":"14","author":"Capiau","year":"2023","journal-title":"Eur Geriatr Med"},{"key":"2025120516111165100_ref10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","article-title":"Benzodiazepine harm: how can it be reduced?","volume":"77","author":"Lader","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"2025120516111165100_ref11","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025120516111165100_ref12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell."},{"key":"2025120516111165100_ref13","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1523\/JNEUROSCI.6506-10.2011","article-title":"Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep","volume":"31","author":"Mieda","year":"2011","journal-title":"J Neurosci"},{"key":"2025120516111165100_ref14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell."},{"key":"2025120516111165100_ref15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron."},{"key":"2025120516111165100_ref16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.neuropharm.2008.06.060","article-title":"Role of lateral hypothalamic orexin neurons in reward processing and addiction","volume":"56","author":"Aston-Jones","year":"2009","journal-title":"Neuropharmacology."},{"key":"2025120516111165100_ref17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.neuroscience.2017.02.038","article-title":"Orexin 2 receptor regulation of the hypothalamic-pituitary-adrenal (HPA) response to acute and repeated stress","volume":"348","author":"Grafe","year":"2017","journal-title":"Neuroscience."},{"key":"2025120516111165100_ref18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell."},{"key":"2025120516111165100_ref19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"2025120516111165100_ref20","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1124\/jpet.115.225466","article-title":"Characterization of JNJ-42847922, a selective orexin-2 receptor antagonist, as a clinical candidate for the treatment of insomnia","volume":"354","author":"Bonaventure","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"2025120516111165100_ref21","doi-asserted-by":"publisher","first-page":"e39131","DOI":"10.1371\/journal.pone.0039131","article-title":"Dual hypocretin receptor antagonism is more effective for sleep promotion than antagonism of either receptor alone","volume":"7","author":"Morairty","year":"2012","journal-title":"PLoS One"},{"key":"2025120516111165100_ref22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"key":"2025120516111165100_ref23","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: a proof-of-concept clinical trial","volume":"91","author":"Hoever","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2025120516111165100_ref24","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsw034","article-title":"Dual orexin receptor antagonist, almorexant, in elderly patients with primary insomnia: a randomized, controlled study","volume":"40","author":"Roth","year":"2017","journal-title":"Sleep."},{"key":"2025120516111165100_ref25","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00228-012-1470-8","article-title":"Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin","volume":"69","author":"Hoch","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"2025120516111165100_ref26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1124\/jpet.117.241422","article-title":"In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist","volume":"362","author":"Beuckmann","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"2025120516111165100_ref27","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1021\/jm100541c","article-title":"Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H\u20131,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia","volume":"53","author":"Cox","year":"2010","journal-title":"J Med Chem"},{"key":"2025120516111165100_ref28","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1007\/s00213-021-05954-0","article-title":"Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia","volume":"238","author":"Roch","year":"2021","journal-title":"Psychopharmacol (Berl)"},{"key":"2025120516111165100_ref29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02244546","article-title":"Effect of zolpidem on sleep and sleep EEG spectra in healthy young men","volume":"104","author":"Brunner","year":"1991","journal-title":"Psychopharmacol (Berl)."},{"key":"2025120516111165100_ref30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"key":"2025120516111165100_ref31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1474-4422(21)00436-1","article-title":"Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials","volume":"21","author":"Mignot","year":"2022","journal-title":"Lancet Neurol"},{"key":"2025120516111165100_ref32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/17425255.2020.1817380","article-title":"Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders","volume":"16","author":"Muehlan","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025120516111165100_ref33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/cts.13470","article-title":"Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: secondary analysis of a randomized clinical trial","volume":"16","author":"Takaesu","year":"2023","journal-title":"Clin Transl Sci"},{"key":"2025120516111165100_ref34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.sleep.2021.01.048","article-title":"Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial","volume":"80","author":"Yardley","year":"2021","journal-title":"Sleep Med"},{"key":"2025120516111165100_ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpet.2025.103624","article-title":"Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist","volume":"392","author":"Hikichi","year":"2025","journal-title":"J Pharmacol Exp Ther"},{"key":"2025120516111165100_ref51","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1021\/acs.jmedchem.9b01787","article-title":"Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis","volume":"63","author":"Rappas","year":"2020","journal-title":"J Med Chem"},{"key":"2025120516111165100_ref44","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1124\/jpet.117.241596","article-title":"The use of physiology-based pharmacokinetic and pharmacodynamic modeling in the discovery of the dual orexin receptor antagonist ACT-541468","volume":"362","author":"Treiber","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"2025120516111165100_ref35","doi-asserted-by":"publisher","first-page":"172","DOI":"10.62641\/aep.v52i2.1659","article-title":"Orexinergic receptor antagonists as a new therapeutic target to overcome limitations of current pharmacological treatment of insomnia disorder","volume":"52","author":"\u00c1lamo","year":"2024","journal-title":"Actas Esp Psiquiatr"},{"key":"2025120516111165100_ref36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/NSS.S201994","article-title":"Targeting orexin receptors for the treatment of insomnia: from physiological mechanisms to current clinical evidence and recommendations","volume":"15","author":"Mogavero","year":"2023","journal-title":"Nat Sci Sleep"},{"key":"2025120516111165100_ref37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41398-025-03439-8","article-title":"Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis","volume":"15","author":"Kishi","year":"2025","journal-title":"Transl Psychiatry"},{"key":"2025120516111165100_ref38","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.1999","article-title":"Efficacy and safety of seltorexant in insomnia disorder: a randomized clinical trial","volume":"82","author":"Mesens","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"2025120516111165100_ref39","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.bmc.2015.01.044","article-title":"Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist","volume":"23","author":"Suzuki","year":"2015","journal-title":"Bioorg Med Chem"},{"key":"2025120516111165100_ref40","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1124\/dmd.108.020479","article-title":"Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds","volume":"36","author":"Obach","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"2025120516111165100_ref41","doi-asserted-by":"publisher","first-page":"5691","DOI":"10.1021\/acs.jmedchem.5b00201","article-title":"Volume of distribution in drug design","volume":"58","author":"Smith","year":"2015","journal-title":"J Med Chem"},{"key":"2025120516111165100_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"2025120516111165100_ref45","doi-asserted-by":"publisher","first-page":"e1183","DOI":"10.1002\/prp2.1183","article-title":"Preclinical metabolism and the disposition of vornorexant\/TS-142, a novel dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"12","author":"Konno","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"2025120516111165100_ref46","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bcpt.13930","article-title":"Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: randomized, double-blind, placebo-controlled phase-1 studies","volume":"133","author":"Kambe","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025120516111165100_ref47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1124\/dmd.120.000229","article-title":"Disposition and metabolism of [14C]lemborexant in healthy human subjects and characterization of its circulating metabolites","volume":"49","author":"Ueno","year":"2021","journal-title":"Drug Metab Dispos"},{"key":"2025120516111165100_ref48","article-title":"Suvorexant common technical","author":"MSD inc","year":"2014"},{"key":"2025120516111165100_ref52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/cpdd.817","article-title":"Pharmacokinetics, pharmacodyna,mics, and safety of the dual orexin receptor antagonist lemborexant: findings from single-dose and multiple-ascending-dose phase 1 studies in healthy adults","volume":"10","author":"Landry","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025120516111165100_ref53","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cpt.1046","article-title":"Accelerated development of the dual orexin receptor antagonist ACT-541468: integration of a microtracer in a first-in-human study","volume":"104","author":"Muehlan","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025120516111165100_ref49","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacol (Berl)"},{"key":"2025120516111165100_ref50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.5664\/jcsm.7036","article-title":"Reference data for polysomnography-measured and subjective sleep in healthy adults","volume":"14","author":"Hertenstein","year":"2018","journal-title":"J Clin Sleep Med"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaf077\/65467451\/pyaf077.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/12\/pyaf077\/65467451\/pyaf077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/28\/12\/pyaf077\/65467451\/pyaf077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T21:11:19Z","timestamp":1764969079000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/doi\/10.1093\/ijnp\/pyaf077\/8340147"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaf077","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,22]]},"article-number":"pyaf077"}}